Ariosa Diagnostics and Fleury Group Announce Offering of the Highly Accurate Harmony™ Prenatal Test in Brazil to Assess Risk for Chromosome Conditions in Singleton and Twin Pregnancies

Download PDF

Sao Paulo, Brazil, Sept. 12, 2013 – Ariosa Diagnostics announced today that it has launched an important partnership with Fleury Medicina e Saúde (Fleury Group) to offer the Harmony™ Prenatal Test to obstetric healthcare providers throughout Brazil, a country with an annual birth rate of 2.99 million. With over 3,000 clinical laboratories and hospitals throughout the country, the Fleury Group has selected the Harmony test as its non-invasive prenatal test of choice for risk analysis of conditions such as Down syndrome.

With technology backed by clinical studies and published in high-impact peer-reviewed medical journals such as Prenatal Diagnosis, Fetal Diagnosis and Therapy and the American Journal of Obstetrics and Gynecology, the Harmony test provides Brazilian clinicians with a reliable, customized prenatal test for identifying the risk of fetal chromosome conditions in pregnant women. The test also includes an option for X and Y chromosome analysis, which provides information on sex chromosome conditions (i.e. Monosomy X or Klinefelter’s syndrome) and fetal sex.

With technology backed by clinical studies and published in high-impact peer-reviewed medical journals such as Prenatal Diagnosis, Fetal Diagnosis and Therapy and the American Journal of Obstetrics and Gynecology, the Harmony test provides Brazilian clinicians with a reliable, customized prenatal test for identifying the risk of fetal chromosome conditions in pregnant women. The test also includes an option for X and Y chromosome analysis, which provides information on sex chromosome conditions (i.e. Monosomy X or Klinefelter’s syndrome) and fetal sex.

Mário Burlacchini, PhD and Coordinator of Fetal Maternal Service at Fleury, said, “Now, we can provide a test with high sensitivity and less risk that generates less anxiety for our pregnant patients. This is a new era in fetal maternal medicine, and Fleury is committed to providing the best for its patients.”


Ken Song, M.D., CEO of Ariosa Diagnostics, said, “We are pleased to have partnered with Fleury to offer the Harmony test to pregnant women in Brazil. Together, we will bring the highest quality and most clinically validated prenatal test for the betterment of prenatal medicine.”